Forte Biosciences (FBRX) Equity Average (2017 - 2026)

Forte Biosciences (FBRX) has 10 years of Equity Average data on file, last reported at $51.5 million in Q1 2026.

• Equity Average for Q1 2026 came in at $51.5 million, up 13.4% year-over-year; the trailing twelve-month figure through Mar 2026 was $51.5 million (up 13.4% YoY), and the FY2025 annual result was $56.7 million, up 29.25% from the prior year.
• Equity Average declined to $51.5 million in Q1 2026 per FBRX's latest filing, from $72.5 million in the prior quarter.
• Over five years, Equity Average peaked at $91.4 million in Q3 2025 and troughed at $13.2 million in Q3 2024.
• A 5-year average of $42.6 million and a median of $39.1 million in 2022 frame the typical range for Equity Average.
• The sharpest annual moves came in 2024 and 2025: Equity Average tumbled 59.68% in 2024, then jumped 594.0% in 2025.
• A 5-year view of Equity Average shows it stood at $40.8 million in 2022, then retreated by 7.26% to $37.9 million in 2023, then retreated by 18.32% to $30.9 million in 2024, then surged by 134.6% to $72.5 million in 2025, then fell by 28.95% to $51.5 million in 2026.
• Business Quant data shows FBRX's Equity Average at $51.5 million in Q1 2026, $72.5 million in Q4 2025, and $91.4 million in Q3 2025.